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different in patients with pre-CPB hemat-
ocrits of 30% as opposed to 40%. Another
advantage of this approach is that it pro-
vided a means of objectively identifying a
threshold for how low nadir hematocrits
may be tolerated according to outcome data.
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Microfibrillar collagen hemostat in
cardiac surgery
To the Editor:
The September 2003 article of S¸ırlak and
associates1 extolled the virtues of microfi-
brillar collagen (MC) as a hemostatic
agent. Studies by our own group support
the conclusion that this compound is highly
effective in cardiac surgery.2 However, I
must sound more than a word of caution.
When in the early 1980s we have ap-
plied MC frequently in the course of heart
operations, we encountered cases of unex-
plained brain injuries. Because we sus-
pected MC as the culprit, the substance was
subjected to extensive in vitro and in vivo
investigation. We found that MC-contain-
ing shed blood, if returned to the circula-
tion by either pump-suction or cell-salvage
devices, may readily pass 40-mm pore-size
filters and lodge in vital organs, including
the brain.3
For this reason, we have recommended
that blood contaminated by MC should not
be reused. Once MC has been applied, only
waste suction should be applied to handle
shed blood.
Francis Robicsek, MD, PhD
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Reply to the Editor:
Despite the use of filters with a pore size of
20 m, the combined use of intraoperative
autotransfusion and microfibrillar collagen
hemostats creates a potential risk for em-
bolization.1 It has been shown that this risk
can be significantly reduced by use of ap-
propriate currently available blood transfu-
sion filters.2 Despite this reduction, we
share the concern of Dr Robicsek that this
substance could pass through different
blood-collecting circuits, which could lead
to organ damage by either direct or induced
embolization, even with the use of com-
mercially available filters.3 For this reason
we applied microfibrillar collagen after
heparin was neutralized by protamine, and
it was not reintroduced into the patient cir-
culation. Moreover, as we stressed in the
Methods section, shed mediastinal blood
was not transfused into any patient.
Mustafa S¸ırlak
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